Phase 1

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Sponsor:

National Cancer Institute (NCI)

Code:

NCT02359565

Conditions

Constitutional Mismatch Repair Deficiency Syndrome

Lynch Syndrome

Malignant Glioma

Recurrent Brain Neoplasm

Recurrent Childhood Ependymoma

Eligibility Criteria

Sex: All

Age: 1 - 30

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Conventional Magnetic Resonance Imaging

Diffusion Tensor Imaging

Diffusion Weighted Imaging

Dynamic Contrast-enhanced MR Perfusion

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information